

## NOVEL EMERGING SUBSTANCES



Axis Forensic Toxicology leads the industry in designer drug testing

### AXIS' NOVEL EMERGING SUBSTANCES PANEL GIVES VISIBILITY TO THE PRESENCE OF THESE COMPOUNDS IN YOUR AREA

#### Why a Novel Emerging Substances Panel?

- Novel substances can disappear as quickly as they appear, placing challenges on laboratories to develop detection methods quickly.
- These compounds are frequently found mixed with other, routinely identified compounds such as fentanyl or methamphetamine.
- In the current focus on public health, many jurisdictions want to be sure they are identifying the full scope of impactful compounds.
- There is insufficient data to determine the impact of a given concentration.
- This panel is designed to be focused on detection and rapidly updated.
- Results are reported qualitatively from our high-resolution screening method using a second aliquot of the specimen.

#### Current Analytes

<b>Alpha-PHP</b>	<b>Desalkylgizapam</b>
<b>Alpha-PiHP</b>	<b>Dex/Levo Medetomidine</b>
<b>AP-237</b>	<b>Dimethylpentylone</b>
<b>AP-238</b>	<b>Flubromazepam</b>
<b>Bromazolam</b>	<b>Phenibut</b>
<b>Brorphine</b>	<b>Tianeptine</b>

Screening for novel emerging compounds is now included with Analyte Assurance™, a feature of Axis' Comprehensive Panels.

SMR372 V6.0 Effective Date 1/22/2024